Drugs / IBI346 CAR-T cell
last change Feb 2024 re-read 3 minutes ago

IBI346 CAR-T cell

Cell therapy

Developed for
refractory plasma cell neoplasm
Investigated by
Chunrui Li · Innovent Biologics (Suzhou) Co. Ltd.

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05266768 Apr 2022 → Feb 2024 refractory plasma cell neoplasm Chunrui Li Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IBI346 CAR-T cell “IBI346 Antibody and IBI346 CAR-T cell injection” NCT05266768 ↗
Modality Cell therapy “IBI346 CAR-T cell” NCT05266768 ↗